Screening of lysosomal storage disorders: Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i

Daniela Ombrone, Sabrina Malvagia, Silvia Funghini, Elisa Giocaliere, Maria Luisa Della Bona, Giulia Forni, Alessio De Luca, Fabio Villanelli, Bruno Casett, Renzo Guerrini, Giancarlo La Marca

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In recent years, new treatments have become available to treat some lysosomal storage disorders (LSDs) and many studies suggest that there is a benefit with starting therapy early. Newborn screening should detect diseases early enough for prompt treatment. Some countries include additional conditions, such as some LSDs, into their newborn screening panels. Mucopolysaccharidosis Type I (MPS I) is an autosomal recessive disorder caused by the deficiency of α-l-iduronidase (IDUA) activity. Currently, enzyme replacement therapy (ERT) or bone marrow transplantation is available and this has raised a growing interest for the development of a newborn screening test. In 2009, we reported a new fast and simplified tandem mass spectrometry-based method for quantifying five enzyme activities on dried blood spots. Here, we describe the inclusion of IDUA activity determination for the simultaneous detection of six lysosomal storage diseases. We have defined reference normal ranges by testing 680 healthy newborns and 240 adults. The assay was checked through three confirmed MPS I patients whose IDUA activity was below the normal range. Reproducibility of the assays has been established by assessing the intra-day and inter-day assay imprecisions. This quick assay has been devised to be implemented in newborn screening by liquid chromatography tandem mass spectrometry.

Original languageEnglish
Pages (from-to)497-503
Number of pages7
JournalEuropean Journal of Mass Spectrometry
Volume19
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Mucopolysaccharidoses
Iduronidase
Liquid chromatography
liquid chromatography
Liquid Chromatography
Mass spectrometry
Assays
Mass Spectrometry
Mucopolysaccharidosis I
Screening
mass spectroscopy
screening
trapping
Newborn Infant
disorders
Reference Values
therapy
Tandem Mass Spectrometry
transplantation
enzyme activity

Keywords

  • A-l-iduronidase
  • Dried blood spot
  • Lysosomal storage disorders
  • Mucopolysaccharidosis type I
  • Online trapping
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Spectroscopy
  • Atomic and Molecular Physics, and Optics
  • Medicine(all)

Cite this

Screening of lysosomal storage disorders : Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i. / Ombrone, Daniela; Malvagia, Sabrina; Funghini, Silvia; Giocaliere, Elisa; Della Bona, Maria Luisa; Forni, Giulia; De Luca, Alessio; Villanelli, Fabio; Casett, Bruno; Guerrini, Renzo; La Marca, Giancarlo.

In: European Journal of Mass Spectrometry, Vol. 19, No. 6, 2013, p. 497-503.

Research output: Contribution to journalArticle

Ombrone, D, Malvagia, S, Funghini, S, Giocaliere, E, Della Bona, ML, Forni, G, De Luca, A, Villanelli, F, Casett, B, Guerrini, R & La Marca, G 2013, 'Screening of lysosomal storage disorders: Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i', European Journal of Mass Spectrometry, vol. 19, no. 6, pp. 497-503. https://doi.org/10.1255/ejms.1257
Ombrone, Daniela ; Malvagia, Sabrina ; Funghini, Silvia ; Giocaliere, Elisa ; Della Bona, Maria Luisa ; Forni, Giulia ; De Luca, Alessio ; Villanelli, Fabio ; Casett, Bruno ; Guerrini, Renzo ; La Marca, Giancarlo. / Screening of lysosomal storage disorders : Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i. In: European Journal of Mass Spectrometry. 2013 ; Vol. 19, No. 6. pp. 497-503.
@article{173aaedcd3204f9c8965e1f2fe455cc3,
title = "Screening of lysosomal storage disorders: Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i",
abstract = "In recent years, new treatments have become available to treat some lysosomal storage disorders (LSDs) and many studies suggest that there is a benefit with starting therapy early. Newborn screening should detect diseases early enough for prompt treatment. Some countries include additional conditions, such as some LSDs, into their newborn screening panels. Mucopolysaccharidosis Type I (MPS I) is an autosomal recessive disorder caused by the deficiency of α-l-iduronidase (IDUA) activity. Currently, enzyme replacement therapy (ERT) or bone marrow transplantation is available and this has raised a growing interest for the development of a newborn screening test. In 2009, we reported a new fast and simplified tandem mass spectrometry-based method for quantifying five enzyme activities on dried blood spots. Here, we describe the inclusion of IDUA activity determination for the simultaneous detection of six lysosomal storage diseases. We have defined reference normal ranges by testing 680 healthy newborns and 240 adults. The assay was checked through three confirmed MPS I patients whose IDUA activity was below the normal range. Reproducibility of the assays has been established by assessing the intra-day and inter-day assay imprecisions. This quick assay has been devised to be implemented in newborn screening by liquid chromatography tandem mass spectrometry.",
keywords = "A-l-iduronidase, Dried blood spot, Lysosomal storage disorders, Mucopolysaccharidosis type I, Online trapping, Tandem mass spectrometry",
author = "Daniela Ombrone and Sabrina Malvagia and Silvia Funghini and Elisa Giocaliere and {Della Bona}, {Maria Luisa} and Giulia Forni and {De Luca}, Alessio and Fabio Villanelli and Bruno Casett and Renzo Guerrini and {La Marca}, Giancarlo",
year = "2013",
doi = "10.1255/ejms.1257",
language = "English",
volume = "19",
pages = "497--503",
journal = "European Journal of Mass Spectrometry",
issn = "1469-0667",
publisher = "I M Publications",
number = "6",

}

TY - JOUR

T1 - Screening of lysosomal storage disorders

T2 - Application of the online trapping-and-cleanup liquid chromatography/mass spectrometry method for mucopolysaccharidosis i

AU - Ombrone, Daniela

AU - Malvagia, Sabrina

AU - Funghini, Silvia

AU - Giocaliere, Elisa

AU - Della Bona, Maria Luisa

AU - Forni, Giulia

AU - De Luca, Alessio

AU - Villanelli, Fabio

AU - Casett, Bruno

AU - Guerrini, Renzo

AU - La Marca, Giancarlo

PY - 2013

Y1 - 2013

N2 - In recent years, new treatments have become available to treat some lysosomal storage disorders (LSDs) and many studies suggest that there is a benefit with starting therapy early. Newborn screening should detect diseases early enough for prompt treatment. Some countries include additional conditions, such as some LSDs, into their newborn screening panels. Mucopolysaccharidosis Type I (MPS I) is an autosomal recessive disorder caused by the deficiency of α-l-iduronidase (IDUA) activity. Currently, enzyme replacement therapy (ERT) or bone marrow transplantation is available and this has raised a growing interest for the development of a newborn screening test. In 2009, we reported a new fast and simplified tandem mass spectrometry-based method for quantifying five enzyme activities on dried blood spots. Here, we describe the inclusion of IDUA activity determination for the simultaneous detection of six lysosomal storage diseases. We have defined reference normal ranges by testing 680 healthy newborns and 240 adults. The assay was checked through three confirmed MPS I patients whose IDUA activity was below the normal range. Reproducibility of the assays has been established by assessing the intra-day and inter-day assay imprecisions. This quick assay has been devised to be implemented in newborn screening by liquid chromatography tandem mass spectrometry.

AB - In recent years, new treatments have become available to treat some lysosomal storage disorders (LSDs) and many studies suggest that there is a benefit with starting therapy early. Newborn screening should detect diseases early enough for prompt treatment. Some countries include additional conditions, such as some LSDs, into their newborn screening panels. Mucopolysaccharidosis Type I (MPS I) is an autosomal recessive disorder caused by the deficiency of α-l-iduronidase (IDUA) activity. Currently, enzyme replacement therapy (ERT) or bone marrow transplantation is available and this has raised a growing interest for the development of a newborn screening test. In 2009, we reported a new fast and simplified tandem mass spectrometry-based method for quantifying five enzyme activities on dried blood spots. Here, we describe the inclusion of IDUA activity determination for the simultaneous detection of six lysosomal storage diseases. We have defined reference normal ranges by testing 680 healthy newborns and 240 adults. The assay was checked through three confirmed MPS I patients whose IDUA activity was below the normal range. Reproducibility of the assays has been established by assessing the intra-day and inter-day assay imprecisions. This quick assay has been devised to be implemented in newborn screening by liquid chromatography tandem mass spectrometry.

KW - A-l-iduronidase

KW - Dried blood spot

KW - Lysosomal storage disorders

KW - Mucopolysaccharidosis type I

KW - Online trapping

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=84893100833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893100833&partnerID=8YFLogxK

U2 - 10.1255/ejms.1257

DO - 10.1255/ejms.1257

M3 - Article

C2 - 24378468

AN - SCOPUS:84893100833

VL - 19

SP - 497

EP - 503

JO - European Journal of Mass Spectrometry

JF - European Journal of Mass Spectrometry

SN - 1469-0667

IS - 6

ER -